UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of exiting the exchange. Redx ...
Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results